Literature DB >> 16240124

Polyurethane stents for lacrimal duct stenoses: 5-year results.

Eckart Bertelmann1, Peter Rieck.   

Abstract

PURPOSE: To present 5-year results of polyurethane stent implantation for treatment of postsaccal lacrimal duct stenoses.
METHODS: Ninety-two consecutive patients admitted to our hospital for stent implantation between 1997 and 2001 were retrospectively analysed. The patients who were not re-treated in our clinic were asked by questionnaire about their satisfaction and complaints.
RESULTS: In 5 patients (5.4%) the implantation was not completed, 38 patients (41.3%) were re-treated due to relapsing epiphora during follow-up, and 11 stents (12.0%) were removed by dacryocystorhinostomy (DCR). Five stents (5.4%) were extracted transnasally. Four stents (4.3%) were removed in another hospital. Eighteen patients (19.6%) had relapsing epiphora but have not been re-treated so far. Forty-nine of 92 patients (53.3%) were not re-treated in our clinic and were interrogated by means of a questionnaire. Twenty-seven answered (55.1%), 8 did not answer (16.3%) and 14 patients (28.6%) did not receive the letter because they had moved away or died. Only 12 of the patients who answered the questionnaire had no or slight complaints (44.4%, or 18.5% of all treated patients).
CONCLUSIONS: The long-term success rate of polyurethane stent implantation is very low (18.5%).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16240124     DOI: 10.1007/s00417-005-0139-8

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  30 in total

1.  When and how nasolacrimal polyurethane stents should be removed?

Authors:  Z Yazici; B Yazici
Journal:  Clin Radiol       Date:  2004-06       Impact factor: 2.350

Review 2.  [Tear outflow. Impact of mucins and TFF-peptides].

Authors:  F Paulsen; A Corfield; M Hinz; W Hoffmann; U Schaudig; A Thale; M Berry
Journal:  Ophthalmologe       Date:  2004-01       Impact factor: 1.059

3.  Balloon catheter dilation for treatment of adults with partial nasolacrimal duct obstruction: a preliminary report.

Authors:  J D Perry; M Maus; T S Nowinski; R B Penne
Journal:  Am J Ophthalmol       Date:  1998-12       Impact factor: 5.258

4.  Nonsurgical placement of a nasolacrimal polyurethane stent.

Authors:  H Y Song; Y H Jin; J H Kim; S J Huh; Y H Kim; T H Kim; K B Sung
Journal:  Radiology       Date:  1995-01       Impact factor: 11.105

5.  [Evaluation of polyurethane stent implantation for the treatment of complete obstruction of the nasolacrimal system: 8-month follow-up and complications].

Authors:  N Anders; K T Hoffmann; N Hosten; T Walkow; R Felix; C Hartmann
Journal:  Ophthalmologe       Date:  1999-10       Impact factor: 1.059

6.  Nonsurgical placement of a nasolacrimal polyurethane stent: long-term effectiveness.

Authors:  H Y Song; Y H Jin; J H Kim; S W Suh; H K Yoon; S G Kang; K B Sung
Journal:  Radiology       Date:  1996-09       Impact factor: 11.105

7.  Nasolacrimal stents in the management of epiphora: medium-term results of a multicenter prospective study.

Authors:  C Lanciego; S De Miguel; M Perea; C Cano; I R García; J Dávila; C Ibarburen; N Toledano; R Rodriguez-Merlo; L G García
Journal:  J Vasc Interv Radiol       Date:  2001-06       Impact factor: 3.464

8.  Nonsurgically placed nasolacrimal stents for epiphora: long-term results and factors favoring stent patency.

Authors:  Sung-Gwon Kang; Ho-Young Song; Duk Hee Lee; Jeong Yol Choi; Hyo-Sook Ahn
Journal:  J Vasc Interv Radiol       Date:  2002-03       Impact factor: 3.464

9.  Treatment of nasolacrimal duct obstruction with polyurethane stent placement: long-term results.

Authors:  Zeynep Yazici; Bülent Yazici; Müfit Parlak; Ercan Tuncel; Haluk Ertürk
Journal:  AJR Am J Roentgenol       Date:  2002-08       Impact factor: 3.959

10.  Retrocaruncular approach to the medial orbit for dacryocystorhinostomy.

Authors:  Jean Paul Adenis; Pierre-Yves Robert
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-08-13       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.